iShares Biotechnology ETF
853 hedge funds and large institutions have $4.68B invested in iShares Biotechnology ETF in 2022 Q2 according to their latest regulatory filings, with 75 funds opening new positions, 220 increasing their positions, 331 reducing their positions, and 98 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
853
Holders Change
-38
Holders Change %
-4.26%
% of All Funds
14.42%
Holding in Top 10
15
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+15.38%
% of All Funds
0.25%
New
75
Increased
220
Reduced
331
Closed
98
Calls
$216M
Puts
$294M
Net Calls
-$77.3M
Net Calls Change
-$109M
Top Buyers
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$49.6M |
| 2 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
+$33.4M |
| 3 |
Jane Street
New York
|
+$23.8M |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$20.2M |
| 5 |
D
Diversified
Wilmington,
Delaware
|
+$17.8M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$139M |
| 2 |
Bessemer Group
Woodbridge,
New Jersey
|
-$46M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$35.8M |
| 4 |
Two Sigma Investments
New York
|
-$35.5M |
| 5 |
JG
Jefferies Group
New York
|
-$29.1M |
